Skip to main content
. 2023 Mar 30;3:46. doi: 10.1038/s43856-023-00273-1

Table 2.

Selected treatment characteristics for discovery cohort.

Locally advanced cancers (n = 100)
No future event of recurrence (n = 72) Future event of recurrence (n = 28) p-value
Neoadjuvant Chemotherapy > 0.99
Anthracycline-Cyclophosphamide (AC) only 1(1.4%) 0 (0%)
AC + Tamoxifen 62 (86%) 24 (86%)
AC + Tamoxifen + Herceptin 8 (11%) 3 (11%)
AC + Tamoxifen + Other 1 (1.4%) 1 (4%)
Herceptin 8 (11%) 3 (11%) > 0.99
Radiation Therapy 58 (81%) 19 (68%) 0.21